Posted in | Nanomaterials

Nanosphere's CTO Joins Select Group of Medical and Biological Engineers and Scientists

Nanosphere, Inc., (NASDAQ: NSPH), announced today that William H. Cork, the company's vice president for research and development and chief technology officer, was inducted into the American Institute of Medical and Biological Engineering's (AIMBE) prestigious College of Fellows at the Institute's annual event at the National Academy of Sciences in Washington, D.C. on February 12, 2009.

(Left to right: AIMBE President Dr. John Watson, Ph.D.; William H. Cork, vice president for research and development and chief technology officer at Nanosphere, Inc.; Cato T. Laurencin, M.D., Ph.D., Vice President for Health Affairs at the University of Connecticut Health Center and Dean of the UConn School of Medicine, who received the 2009 Pierre Galletti Award, the highest honor bestowed annually by the AIMBE)

Mr. Cork was one of 96 newly elected Fellows of AIMBE, who joined the other 900 distinguished scientists and engineers as leaders in the development of biomedical devices and processes, treatment of diseases, and public policy related to all aspects of medical and biological engineering." In presenting the award to Mr. Cork, Jennifer Ayers, AIMBE's Executive Director, noted his accomplishments "for the development of highly sensitive molecular diagnostic systems based on nanotechnology as well as important blood separation technologies."

As head of research and development at Nanosphere, Mr. Cork led the company's effort to develop the The Verigene® System, an FDA-approved molecular diagnostics workstation that utilizes patented gold nanoparticle technology to detect nucleic acid and protein targets of interest for a variety of applications. Under Mr. Cork's leadership, Nanosphere also received the FDA's first clearance of a test to determine an individual's ability to metabolize the anti-coagulant medication warfarin, information critical to determining safe and appropriate dosing, on the nanotechnology based Verigene® System.

Commenting on Mr. Cork's induction into the AIMBE College of Fellows, William P. Moffitt, Nanosphere's president and chief executive officer, said, "We are extremely proud of Bill Cork and the cutting-edge research that he and his team have done in the development of our Verigene system. It is not surprising to us that his work has now been recognized by the American Institute of Medical and Biological Engineers, and he takes his rightful place among the leading scientists and engineers who have made their mark on the world of biomedical engineering."

Mr. Cork joined Nanosphere as vice president of research and development and chief technology officer at the inception of the company in 2000. Previously, he had developed a blood separation system at Baxter Healthcare, and holds numerous technology patents.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback